Document Detail


Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients.
MedLine Citation:
PMID:  15807182     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cardiovascular complications are the leading cause of mortality in patients with end-stage renal disease. Left ventricular hypertrophy (LVH) is recognized as an independent risk factor for cardiovascular morbidity and mortality. At the onset of dialysis, more than 70% of the patients with chronic kidney disease have echocardiographic evidence of LVH. Anemia, increased red cells filterability time (RCFT), and blood viscosity are known to induce LVH. AIM: To evaluate, prospectively, the effects of erythropoietin (EPO) therapy for 20 weeks on RCFT and left ventricular mass (LVM). PATIENTS AND METHODS: Twenty uremic and anemic predialysis patients with creatinine clearance test below 35 mL/min were studied. RCFT test and three-dimensional echocardiography were performed at 0, 10, and 20 weeks. RESULTS: EPO therapy for 20 weeks did not adversely affect renal function and did not significantly change the mean blood pressure. It significantly increased the hemoglobin and fibrinogen levels, and decreased RCFT and LVM (p < .01). CONCLUSION: Although correction of anemia can contribute to regression of LVM, we speculate that an increasing number of cells with normalized viscoelastic properties and a direct effect of EPO on erythrocytes and myocardiocytes, through specific receptors, may also play an important role.
Authors:
Kamal Hassan; Nathan Roguin; Yan Kaganov; Shadi Hasan; Batya Kristal
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Renal failure     Volume:  27     ISSN:  0886-022X     ISO Abbreviation:  Ren Fail     Publication Date:  2005  
Date Detail:
Created Date:  2005-04-05     Completed Date:  2005-06-09     Revised Date:  2008-05-21    
Medline Journal Info:
Nlm Unique ID:  8701128     Medline TA:  Ren Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  177-82     Citation Subset:  IM    
Affiliation:
Nephrology and Hypertension Department, Western Galilee Hospital, Nahariya, Israel. drkamalh@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia / drug therapy
Echocardiography, Three-Dimensional
Erythrocyte Deformability* / drug effects*
Erythropoietin, Recombinant / therapeutic use*
Female
Humans
Hypertrophy, Left Ventricular / prevention & control*
Kidney Failure, Chronic / complications,  drug therapy
Male
Prospective Studies
Renal Dialysis
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodia...
Next Document:  Effect of off-pump and on-pump coronary artery bypass grafting on renal function.